We compared the clinical and CSF findings, including carcinoembryonic antigen (CEA), between CM and non-CM patients, and explored the diagnostic markers for early identification of CM as well as the contributing factors for mortality. This evidence concerns the gene CEACAM5 and cutaneous mastocytosis.